ABIVAX has a diversified product portfolio that leverages three technology platforms for drug discovery:
- an anti-viral platform that modulates RNA splicing in a variety of viral diseases
- an immune enhancement platform that functions as an iNKT-based immune enhancer for the treatment of chronic viral infections and potentially also cancer,
- a polyclonal antibody platform for the development of novel prophylaxis and treatment options for patients with Ebola.
Based on these platform technologies, ABIVAX’s product candidates are targeting the human immune response with the aim to cure chronic viral diseases.